CDTX
Company Description
Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Track Record
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.27M | 23.28M | 64.45M | 49.57M | 12.07M | 20.91M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (169.83M) | (22.93M) | (33.58M) | (42.47M) | (72.11M) | (41.09M) | (59.02M) | (55.73M) | (48.16M) | (32.19M) | (11.89M) | (1.34M) |
| EPS | -26.75 | -5.25 | -9.61 | -16.20 | -36.03 | -26.78 | -45.62 | -63.69 | -66.49 | -46.76 | -290.15 | -83.04 |
| Free Cash Flow | (176.66M) | (22.94M) | (28.59M) | (25.27M) | (54.60M) | (28.57M) | (56.88M) | (50.22M) | (40.17M) | (27.13M) | (8.70M) | (1.05M) |
| FCF / Share | -27.82 | -5.25 | -8.19 | -9.64 | -26.28 | -19.09 | -43.97 | -57.39 | -55.45 | -39.40 | -212.26 | -64.76 |
| Operating CF | (176.53M) | (22.43M) | (28.47M) | (25.23M) | (54.41M) | (28.53M) | (56.70M) | (49.91M) | (39.77M) | (25.96M) | (7.71M) | (1.05M) |
| Total Assets | 214.80M | 67.03M | 47.49M | 75.33M | 60.42M | 68.98M | 79.11M | 79.03M | 106.96M | 109.97M | 24.35M | 201,000 |
| Total Debt | 3.58M | 4.88M | 1.21M | 5.06M | 7.96M | 11.72M | 9.93M | 9.87M | 9.79M | 0 | 0 | 1.48M |
| Cash & Equiv | 189.82M | 35.78M | 32.73M | 62.27M | 35.91M | 50.27M | 74.56M | 75.31M | 104.62M | 107.51M | 22.80M | 185,000 |
| Book Value | 163.31M | (8.21M) | (14.44M) | 21.57M | 10.71M | 37.84M | 59.14M | 59.74M | 88.18M | 103.91M | 21.10M | (1.40M) |
| Return on Equity | -1.04 | N/A | N/A | -1.97 | -6.73 | -1.09 | -1.00 | -0.93 | -0.55 | -0.31 | -0.56 | N/A |
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 302,000 | 973,000 | 17.58M | 9.22M | 5.09M | 26.11M | 10.22M |
| Net Income | (83.23M) | (25.72M) | (23.48M) | (52.31M) | (15.98M) | (91.21M) | (10.33M) | (5.61M) | (9.11M) | (13.62M) | 3.01M | (13.38M) |
| EPS | -3.10 | -1.65 | -1.66 | -5.37 | -2.38 | -19.59 | -2.28 | -1.25 | -1.81 | -2.80 | 0.77 | -3.72 |
| Free Cash Flow | (40.62M) | (40.96M) | (21.95M) | (29.41M) | (36.80M) | (103.78M) | (6.67M) | (12.90M) | (1.76M) | 2.71M | (10.99M) | (21.01M) |
| FCF / Share | -2.61 | -2.63 | -1.55 | -3.02 | -5.64 | -22.74 | -1.47 | -2.87 | -0.39 | 0.62 | -2.80 | -5.84 |
| Operating CF | (40.62M) | (40.96M) | (21.95M) | (29.41M) | (36.70M) | (103.78M) | (6.64M) | (12.72M) | (1.63M) | 2.82M | (10.90M) | (21.00M) |
| Total Assets | 518.65M | 534.33M | 191.73M | 214.80M | 162.33M | 173.36M | 52.72M | 67.03M | 63.47M | 67.99M | 81.74M | 47.49M |
| Total Debt | 1.98M | 2.33M | 2.67M | 3.58M | 3.94M | 4.30M | 4.65M | 4.88M | 4.36M | 4.54M | 1.00M | 1.21M |
| Cash & Equiv | 293.65M | 510.57M | 168.15M | 189.82M | 127.39M | 164.37M | 29.02M | 35.78M | 48.67M | 50.43M | 47.98M | 32.73M |
| Book Value | 422.39M | 501.17M | 141.68M | 163.31M | 115.63M | 130.94M | (17.78M) | (8.21M) | 8.04M | 15.41M | 26.84M | (14.44M) |
| Return on Equity | -0.20 | -0.05 | -0.17 | -0.32 | -0.14 | -0.70 | N/A | N/A | -1.13 | -0.88 | 0.11 | N/A |
